May 20, 2026
The Pharmaceutical Industry Labor-Management Association (PILMA) issued the following
statement in response to the potential inclusion of a Most Favored Nation drug pricing proposal
ahead of an anticipated vote on the Senate’s budget reconciliation bill. While we believe it is
crucial that policymakers prioritize making healthcare more affordable for American families,
importing foreign price controls is not the solution — and union workers across this country will
pay a serious price if it moves forward.
The biopharmaceutical industry has committed to investing nearly $600 billion in the United
States. These investments are already creating jobs for union pipefitters, electricians,
ironworkers, and other skilled trades workers who build and maintain the facilities where life-
saving innovation is developed. MFN pricing would put that momentum at risk, depressing the
R&D and capital investment that sustains these jobs in communities across the country.
Instead of targeting the manufacturers who are bringing jobs and investment back to America,
lawmakers should direct their attention toward vertically integrated insurance corporations and
their affiliated pharmacy benefit managers. These middlemen have long profited from a system
built on opacity, intercepting savings that should flow to patients and driving up costs
throughout the supply chain without contributing a dollar to the development of new
medicines.
PILMA stands ready to be a constructive partner in advancing solutions that protect American
workers, strengthen innovation, and deliver real affordability for patients. MFN pricing is not
that solution.